Ultragenyx Pharmaceutical Q3 EPS $(1.16) Misses $(1.12) Estimate, Sales $173.000M Miss $183.118M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1.12) by 3.57 percent. This is a 35.91 percent increase over losses of $(1.81) per share from the same period last year. The company reported quarterly sales of $173.000 million which missed the analyst consensus estimate of $183.118 million by 5.53 percent. This is a 8.17 percent increase over sales of $159.933 million the same period last year.